What is clinically relevant? [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2018-04-06 22:05 (1296 d 06:48 ago) – Posting: # 18649
Views: 4,766

Hi BF,

» I believe the spaghetti plots you posted are actually indicative of a infusion of unbound drug.
» Release of the encapsulated form follows first order kinetics and is Sequential - kind of like metabolic clearance from parent --> metabolite.

Did you notice the different concentrations scales (encapsulated doxorubicin: µg/mL, free: ng/mL)? On the average free is less than 1% of encapsulated. With just three sampling times during infusion I would say it is not possible to separate zero order (encapsulated) from first order (release from the liposomes).

» Luckily, you also posted the parent/metabolite curve for doxorubinol. Because of similarity in process, if no free drug is infused, bound and unbound PK should follow the same general shape we see in parent + metabolite.

What do you mean by bound + unbound? Encapsulated and free?

» The fact that total + free dox concentrations are colinear is pretty strong evidence for co-infusion of bound + unbound.

I still don’t think so. The release can be quite quick. Hence, the shapes looks similar but the concentrations of free doxo are always pretty low compared to encapsulated doxo.

» Further, the fact that there isn't a lag time in unbound, as well as a nonlinear shape, is evidence, too.

Again, I would contradict that. I don’t expect a lag-time. I would rather say that doxo follows [image] Le Chatelier’s principle and is simply driven out from the liposomes due to the concentration gradient (Cliposomes > Cblood).

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,753 posts in 4,548 threads, 1,544 registered users;
online 22 (0 registered, 22 guests [including 6 identified bots]).
Forum time: Sunday 04:53 CEST (Europe/Vienna)

They were “so intent of making everything numerical”
that they frequently missed seeing
what was there to be seen.    Barbara McClintock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz